Cardiovascular diseases—including heart attacks, strokes, and peripheral vascular disease represent the most prevalent causes of death in developed countries. That means that any innovative cardiovascular PET imaging procedures would be of benefit for patients.
Life Molecular Imaging is investigating 18F-GP1, a small fluorine-18-labeled molecule for detection of activated platelets during thrombus formation. 18F-GP1 is currently in phase I of clinical development.
Preclinical and initial clinical results have been published recently.
Source: Journal of Nuclear Medicine Cover Image, July 1, 2017; 58(7). The cover image is artwork presented in Lohrke et al. (2017) reporting about “18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi”
For additional information see also the accompanying SNMMI press release.
Selected publications on 18F-GP1:
- Kim C. et al. (2018) Glycoprotein IIb/IIIa receptor imaging with 18F-GP1 positron emission tomography for acute venous thromboembolism: an open-label, non-randomized, first-in-human phase 1 study. J Nucl Med. 2018 (ahead of print)
- Lohrke J et al. (2017) 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. J Nucl Med. 2017 Jul;58(7):1094-1099. https://www.ncbi.nlm.nih.gov/pubmed/28302764